http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Adaptive Neuro-Fuzzy Algorithm for Pitch Control of Variable-speed Wind Turbine
Aamer Bilal Asghar,Khazina Naveed,Gang Xiong,Yong Wang 제어·로봇·시스템학회 2022 International Journal of Control, Automation, and Vol.20 No.11
With increasing size of wind turbines (WTs), the power regulation and fatigue loads on WT structures emerge as major problems to wind power industry. Pitch angle is scheduled above the rated wind speed to keep the power captured by variable-speed wind turbine (VSWT) around its rated value and release the fatigue load on WT structure. In this paper, a hybrid intelligent learning based adaptive neuro-fuzzy algorithm is proposed to schedule the pitch angle of 2 Megawatt (MW) VSWT. The artificial neural network (ANN) trains the parameters of fuzzy membership functions (MFs) using least squares estimator method in forward pass and back propagation gradient descent method in backward pass. The simulation is done in MATLAB and results are compared with multilayer perceptron feed-forward neural network (MLPFFNN) and fuzzy logic-based pitch controllers. The results indicate the effectiveness of proposed neuro-fuzzy algorithm which outperforms the other two methods.
Clofarabine in the Treatment of Elderly Patients with Acute Myeloid Leukemia
Aleem, Aamer,Anjum, Farhan,Algahtani, Farjah,Iqbal, Zafar,Alsaleh, Khalid,AlMomen, Abdulkareem Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.2
Background: Elderly patients with acute myeloid leukemia (AML) have a poor outcome because of co-morbidities, poor tolerance to intensive chemotherapy and inherently more resistant disease. Clofarabine is a second generation nucleoside analogue which has shown promising activity in elderly patients with AML. This study was conducted to review the outcome of treatment with clofarabine in a group of such patients. Methods: The records of 5 elderly patients who were diagnosed to have AML and treated with clofarabine over a 12 month period were reviewed retrospectively. Results: There were 2 female and 3 male patients with a median age of 68 years (range 65-82). At the time of treatment, 2 patients had newly diagnosed AML not considered suitable for intensive therapy, while 3 patients had partial or no response to conventional chemotherapy. The overall response rate was 100%, all patients achieving a complete remission. Induction and consolidation were well tolerated. All patients developed neutropenia with a median duration of 20 days (range 17-42). One patient developed hand and foot syndrome and a generalized rash but recovered. There was no mortality and all patients remained in remission after a median follow-up of 5.2 months (Range 3-10). Conclusion: Clofarabine (alone or in combination) is active in elderly AML patients with an acceptable safety profile and should be considered a potential option in this group.
Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients in Saudi Arabia
Aleem, Aamer,Diab, Abdul Rahman Al,Alsaleh, Khalid,Algahtani, Farjah,Alsaeed, Eyad,Iqbal, Zafar,El-Sherkawy, Mohamed Sherif Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.4
Objectives: Thrombotic risk is increased in patients with cancer and there are important implications for those who suffer a venous thromboembolism (VTE). We undertook this study to determine the frequency, clinical patterns, and outcome of VTE in Saudi patients with cancer. Methods: Cancer (solid tumors and lymphoma) patients who developed VTE from January 2004 to January 2009 were studied retrospectively. Demographics and clinical characteristics related to thrombosis and cancer were evaluated. Results: A total of 701 patients with cancer were seen during the study period. VTE was diagnosed in 47 (6.7%) patients (median age 52, range 18-80 years). Lower limb DVT was the most common type, seen in 47% patients, followed by PE in 19%, and 19% patients had both DVT & PE. Thrombosis was symptomatic in 72% patients while it was an incidental finding on routine workup in 28%. Cancer and VTE were diagnosed at the same time in 38% of patients, and 47% patients developed VTE during the course of disease after the cancer diagnosis. The majority of VTE post cancer diagnoses occurred during the first year (median 4 months, range 1-14). Additional risk factors for VTE were present in 22 (47%) patients and 14 (30%) of these patients were receiving chemotherapy at the time of thrombosis. Only 5 (10.6%) patients were receiving thrombo-prophylaxis at the time of VTE diagnosis. Most common types of tumors associated with thrombosis were breast cancer, non-Hodgkin's lymphoma and lung cancer. The majority of the affected patients (79%) had advanced stage of cancer. After a median follow-up of 13 (range 0.5-60) months, 38 (81%) patients had died. There was no difference in the mortality of patients with symptomatic or asymptomatic thrombosis (82% vs 78.6%). Conclusions: Thrombotic complications can develop in a significant number of patients with cancer, and almost half of the patients have additional risk factors for VTE. Thrombosis is usually associated with advanced disease and can be asymptomatic in more than a quarter of cases. Thromboprophylaxis in cancer patients is under-utilized. Community based studies are needed to accurately define the extent of this problem and to develop effective prophylactic strategies.
Movability Number as the Parameter of Sediment Incipient Motion: A Mathematical Approach
Bhat Aamer Majid,Ahanger Manzoor Ahmad,Mohapatra Pranab Kumar 한국해양과학기술원 2023 Ocean science journal Vol.58 No.4
In fluvial sediment transport, the sediment threshold parameter Movability Number, which is the ratio of the shear velocity and the settling velocity of a sediment particle, is seen as a potential replacement for the traditional Shields parameter. Until now, the studies carried out on Movability Number have been mostly empirical or crudely analytical. In the current study, a mathematical modeling approach is attempted. Steady unidirectional flow is considered and the mode of entrainment is taken as that of rolling, with a compact sediment bed. The mathematical relationships developed here express the Movability Number as a function of either shear Reynolds number or dimensionless grain diameter. Comparisons are made with both experimental data and previous empirical formulae. The developed model is a novel approach to study the Movability Number, which bears satisfactory nearness to the previous studies. The deviation produced in terms of underestimation is due to the rolling mode of motion, which requires the least disturbing energy. The developed model can be improved by the consideration of turbulence in future studies.
Saeed, Aamer,Shahzad, Danish,Larik, Fayaz Ali,Channar, Pervaiz Ali,Mahfooz, Haroon,Abbas, Qamar,Hassan, Mubashir,Raza, Hussain,Seo, Sung-Yum,Shabir, Ghulam Bangladesh Journals Online 2017 Bangladesh journal of pharmacology Vol.12 No.2
<P><p>A series of 4-aryl-2,6-dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyri-dines 6a-6h were prepared by using the one-pot three component synthetic method. The target compounds 6a-6h were synthesized by reacting two molar equivalents of ketone functionality and one mole of aromatic aldehydes in ammonium acetate to obtain the desired products. The structures of newly synthesized compounds were characterized by FT-IR, 1H-NMR, 13C-NMR, and elemental analysis. All the synthesized compounds were screened for their elastase inhibition and antioxidant activity. Almost all of the com-pounds 6a-h showed good to excellent activities against elastase enzyme more than the reference drug. Compounds 6d and 6b at 0.2 ± 0.0 µM and 0.2 ± 0.0 µM were found to most potent derivatives against elastase enzyme. Compound 6a exhibited prominent free radical scavenging activity. From the results of the biological activity, we infer that some derivatives can serve as lead molecules in pharmacology.</p><p><strong>Video Clip of Methodology</strong>:</p><p>3 min 13 sec <a href='https://youtube.com/v/gPLdpGpZhR8'>Full Screen</a> <a href='https://youtube.com/watch?v=gPLdpGpZhR8'>Alternate</a></p></P>
Bhutta, M. Aamer Rafique,Tsuruta, Ken,Ohama, Yoshihiko Korea Concrete Institute 2008 International Journal of Concrete Structures and M Vol.2 No.1
This experimental study examines the applicability of polymer mortar permanent forms using a methyl methacrylate (MMA) solution of waste expanded polystyrene (EPS) to develop effective recycling processes for the EPS, referring to the flexural behavior of a polymer-impregnated mortar permanent form with almost the same performance as commercial products. An MMA solution of EPS is prepared by dissolving EPS in MMA, and unreinforced and steel fiber-reinforced polymer mortars are mixed using the EPS-MMA-based solution as a liquid resin or binder. Polymer mortar permanent forms (PMPFs) using the EPS-MMA-based polymer mortars without and with steel fiber and crimped wire cloth reinforcements and steel fiber-reinforced polymer-impregnated mortar permanent form (PIMPF) are prepared on trial, and tested for flexural behavior under four-point (third-point) loading. The EPS-MMAbased PMPFs are more ductile than the PIMPF, and have a high load-bearing capacity. Consequently, they can replace PIMPF in practical applications.
Journey of the ALK-inhibitor CH5424802 to phase II clinical trial
Muhammad Latif,Aamer Saeed,김성환 대한약학회 2013 Archives of Pharmacal Research Vol.36 No.9
The anaplastic lymphoma kinase (ALK) receptortyrosine kinase represents a potential therapeutic target. Specially, a variety of alterations in the ALK geneincluding mutations, overexpression, amplification, translocationsand structural rearrangements, are involved inhuman cancer tumorigenesis. The second-generation ALKinhibitor CH5424802 (development code: AF802; ChugaiPharmaceutical, a subsidiary of Roche) achieves tumorregression with excellent tolerance and shows promisingefficacy in patients with ALK-positive non-small cell lungcancer. CH5424802 shows good kinase selectivity, has apromising pharmacokinetics profile, and has strong antiproliferativeactivity in several ALK-driven tumor models. CH5424802 has also shown anti-tumor activity in mousexenograft studies. Here, we summarize recent advances andthe evidence that CH5424802 acts as an ALK inhibitor. We also discuss its potential for further development as ananticancer drug in clinical trials.